Latest Affinium Pharmaceuticals Stories
LAUSANNE, Switzerland, February 11, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs
AUSTIN, TEXAS, May 2 /PRNewswire/ - Affinium Pharmaceuticals announced today the results of a new multiple ascending dose Phase I study of its novel, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation. The study examined the tolerability, safety and pharmacokinetics of immediate release tablets of AFN-1252.
AUSTIN, March 15 /PRNewswire/ - Affinium Pharmaceuticals, a clinical-stage drug development company with a novel, specific-spectrum anti-staphylococcal antibiotic, announced today that Dr. Barry Hafkin, Chief Medical Officer, and Dr.
- A person in a secondary role, specifically the second most important character (after the protagonist).